Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

The Recombinant DNA Technology Market size is expected to be worth around USD 1288.5 Bn by 2032 from USD 786.7 Bn in 2023, growing at a CAGR of 5.8% As scientific and technological advancements ...